Skip to main content

Advertisement

SpringerLink
Log in

The impact of new data in the treatment of advanced hepatocellular carcinoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, causing 500,000 deaths yearly. The risk factors mostly responsible for the rising incidence of HCC in the Western hemisphere are hepatitis C, alcoholic cirrhosis, and nonalcoholic steatohepatitis, which most commonly leads to HCC in the setting of cirrhosis. Over the past 30 years, several chemotherapeutic single agents and combinations have been tested in HCC, yet none have demonstrated any improvement in survival. Recently, the multitargeted anti-angiogenic and Raf kinase inhibitor sorafenib has shown a survival advantage as a single agent and improved outcomes in combination with doxorubicin. Other novel agents have also shown intriguing outcomes as single agents (sunitinib) or in combination (bevacizumab and erlotinib). The encouraging results and clinical information gathered in recent trials are generating important clinical questions regarding which patients to treat, how to accommodate concurrent cirrhosis, and which parameters to use to monitor efficacy and the potential benefit from therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Parkin DM, Bray F, Ferlay J, et al.: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153–156.

    Article  PubMed  CAS  Google Scholar 

  2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745–750.

    Article  PubMed  CAS  Google Scholar 

  3. Llovet J, Ricci S, Mazzaferro V, et al.: the SHARP Investigators Study Group: Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial) [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):LBA1.

  4. McGlynn KA, Tsao L, Hsing AW, et al.: International trends and patterns of primary liver cancer. Int J Cancer 2001, 94:290–296.

    Article  PubMed  CAS  Google Scholar 

  5. Morgan TR, Mandayam S, Jamal MM: Alcohol and hepatocellular carcinoma. Gastroenterology 2004, 127(Suppl 1):S87–S96.

    Article  PubMed  CAS  Google Scholar 

  6. Calle EE, Teras LR, Thun MJ: Obesity and mortality. N Engl J Med 2005, 353:2197–2199.

    Article  PubMed  CAS  Google Scholar 

  7. El-Serag HB, Richardson PA, Everhart JE: The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001, 96:2462–2467.

    Article  PubMed  CAS  Google Scholar 

  8. Huitzil FD, Capanu M, Jacobs G, et al.: Prognostic factors (PF) in advanced hepatocellular carcinoma (AHCC): multivariate analysis and comparison between staging systems (SS) in patients (pts) treated at Memorial Sloan-Kettering Cancer Center (MSKCC) [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4601.

    Google Scholar 

  9. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646–649.

    Article  PubMed  CAS  Google Scholar 

  10. Child CG: The Liver and Portal Hypertension. Philadelphia: Saunders; 1964:50.

    Google Scholar 

  11. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000, 31:840–845.

  12. Leung TW, Tang AM, Zee B, et al.: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94:1760–1769.

    Article  PubMed  Google Scholar 

  13. Chevret S, Trinchet JC, Mathieu D, et al.: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinoma Hepatocellulaire. J Hepatol 1999, 31:133–141.

    Article  PubMed  CAS  Google Scholar 

  14. Okuda K, Ohtsuki T, Obata H, et al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918–928.

    Article  PubMed  CAS  Google Scholar 

  15. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003, 38:207–215.

    Article  PubMed  Google Scholar 

  16. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329–338.

    Article  PubMed  CAS  Google Scholar 

  17. Cillo U, Vitale A, Grigoletto F, et al.: Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006, 44:723–731.

    Article  PubMed  Google Scholar 

  18. Collette S, Bonnetain F, Paoletti X, et al.: Prognosis of hepatocellular carcinoma (HCC): comparison of four staging systems in two French clinical trials [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4589.

    Google Scholar 

  19. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127(Suppl 1):S27–S34.

    Article  PubMed  Google Scholar 

  20. Barbare JC, Ballet F, Petit J, et al.: Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation [in French]. Bull Cancer 1984, 71:442–445.

    PubMed  CAS  Google Scholar 

  21. Olweny CL, Med M, Toya T, et al.: Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975, 36:1250–1257.

    Article  PubMed  CAS  Google Scholar 

  22. Choi TK, Lee NW, Wong J: Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 1984, 53:401–405.

    Article  PubMed  CAS  Google Scholar 

  23. Simonetti RG, Liberati A, Angiolini C, et al.: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997, 8:117–136.

    Article  PubMed  CAS  Google Scholar 

  24. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97:1532–1538.

    Article  PubMed  CAS  Google Scholar 

  25. Porta C, Ruff P, Feld R, et al.: Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX) [abstract 97]. Presented at the 2006 Gastrointestinal Cancers Symposium. January 26–28, 2006; San Francisco, CA. Abstract 97.

  26. Leung TW, Patt YZ, Lau WY, et al.: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5:1676–1681.

    PubMed  CAS  Google Scholar 

  27. Abou-Alfa GK, Morse M: Novel therapies targeted at signal transduction in liver tumors. In Malignant Liver Tumors: Current and Emerging Therapies, edn 2. Edited by Clavien PA. Sudbury: Jones and Bartlett; 2004:307.

    Google Scholar 

  28. Kira S, Nakanishi T, Suemori S, et al.: Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997, 17:177–182.

    PubMed  CAS  Google Scholar 

  29. Hamazaki K, Yunoki Y, Tagashira H, et al.: Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev 1997, 21:355–360.

    PubMed  CAS  Google Scholar 

  30. Philip PA, Mahoney MR, Allmer C, et al.: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657–6663.

    Article  PubMed  CAS  Google Scholar 

  31. Huether A, Hopfner M, Varadari V, et al.: EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular carcinoma. Biochem Pharmacol 2005, 70:1568–1578.

    Article  PubMed  CAS  Google Scholar 

  32. Ramanathan RK, Belani CP, Singh DA, et al.: Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). a California Consortium (CCC-P) trial [ASCO abstract 4010]. J Clin Oncol 2006, 24:abstract 4010.

    Google Scholar 

  33. Yoshiji H, Kuriyama S, Yoshii J, et al.: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004, 39:1517–1524.

    Article  PubMed  CAS  Google Scholar 

  34. Zhang T, Sun HC, Xu Y, et al.: Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. Clin Cancer Res 2005, 11:8557–8563.

    Article  PubMed  CAS  Google Scholar 

  35. Wilhelm SM, Carter C, Tang L, et al.: BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099–7109.

    Article  PubMed  CAS  Google Scholar 

  36. Strumberg D, Richly H, Hilger RA, et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005, 23:965–972.

    Article  PubMed  CAS  Google Scholar 

  37. Abou-Alfa GK, Schwartz L, Ricci S, et al.: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:4293–4300.

    Article  PubMed  CAS  Google Scholar 

  38. Giambartolomei S, Covone F, Levrero M, Balsano C: Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001, 20:2606–2610.

    Article  PubMed  CAS  Google Scholar 

  39. Chen J, Siddiqui A: Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. J Virol 2007, 81:6757–6760.

    Article  PubMed  CAS  Google Scholar 

  40. Abou-Alfa G, Amadori D, Santor A, et al.: Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis [abstract 140]? Presented at the 2008 Gastrointestinal Cancers Symposium. January 25–27, 2008; Orlando, FL.

  41. Abou-Alfa G, Johnson P, Knox J, et al.: Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Presented at the 14 th Annual Meeting of the European Cancer Conference. September 23–27, 2007; Barcelona, Spain.

  42. Schwartz JD, Schwartz M, Lehrer D, et al.: Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [ASCO abstract 4144]. J Clin Oncol 2006, 24.

  43. Schwartz JD, Schwartz M, Goldman J, et al.: Bevacizumab in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [abstract 134]. Presented at the 2005 Gastrointestinal Cancer Symposium. January 27–29, 2005; Hollywood, CA.

  44. Malka D, Dromain C, Farace F, et al.: Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4570.

    Google Scholar 

  45. Zhu AX, Blaskowsky LS, Ryan DP, et al.: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898–1903.

    Article  PubMed  CAS  Google Scholar 

  46. Sun W, Haller DG, Mykulowycz K, et al.: Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4574.

    Google Scholar 

  47. Hsu C, Yang T, Hsu C, et al.: Modified-dose capecitabine + bevacizumab for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): a phase II, single-arm study [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):15190.

    Google Scholar 

  48. Thomas MB, Chadha R, Iwasaki M, et al.: The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4567.

    Google Scholar 

  49. Zhu AX, Sahani DV, di Tomaso E, et al.: A phase II study of sunitinib in patients with advanced hepatocellular carcinoma [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):4637.

    Google Scholar 

  50. Faivre SJ, Raymond E, Douillard J, et al.: Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC) [ASCO abstract]. J Clin Oncol 2007, 25(18S Suppl):3546.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10022, USA

    Ghassan K. Abou-Alfa

Authors
  1. Ghassan K. Abou-Alfa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan P. Venook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghassan K. Abou-Alfa.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abou-Alfa, G.K., Venook, A.P. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr Oncol Rep 10, 199–205 (2008). https://doi.org/10.1007/s11912-008-0031-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0031-x

Keywords

Search

Navigation